, NURS 5334 Advanced Pharmacology: Master
Antimicrobial Stewardship &
Pharmacodynamics Practice Questions &
Detailed Explanations
Subject: NURS 5334 – Antimicrobial Pharmacotherapy and Advanced Clinical
Management
Question 1: A patient with a documented history of severe IgE-mediated hypersensitivity to
penicillin presents with a complex skin and soft tissue infection caused by MRSA. Which of the
following represents the most appropriate evidence-based selection, considering
pharmacodynamic safety and efficacy?
A) Cefazolin, administered with aggressive desensitization protocols.
B) Ceftriaxone, as the risk of cross-reactivity with third-generation cephalosporins is negligible.
C) Vancomycin, with targeted trough monitoring to ensure appropriate area under the curve
(AUC) targeting.
D) Imipenem-cilastatin, which exhibits a broad-spectrum profile suitable for multi-drug resistant
pathogens.
Correct Answer: C) Vancomycin, with targeted trough monitoring to ensure appropriate
area under the curve (AUC) targeting.
*Explanation: In a patient with a severe type I penicillin allergy, avoiding all beta-lactams is the
safest clinical approach when alternatives exist. Vancomycin remains the gold standard for
MRSA. AUC/MIC targeting is the current standard of practice to maximize efficacy and
minimize nephrotoxicity, unlike trough-only monitoring which is now considered outdated.
Question 2: An immunocompromised patient is diagnosed with invasive pulmonary
aspergillosis. Which pharmacodynamic property is critical to consider when initiating therapy
with Voriconazole?
A) Voriconazole acts as a potent inducer of the CYP3A4 enzyme system, requiring dosage
reductions of concomitant immunosuppressants.
B) Voriconazole exhibits non-linear, dose-dependent pharmacokinetics due to the saturation of
its metabolic pathways.
, C) Voriconazole is primarily excreted via renal filtration, necessitating significant dose
adjustments in patients with chronic kidney disease.
D) Voriconazole binds irreversibly to fungal ergosterol, leading to immediate cell membrane
lysis.
Correct Answer: B) Voriconazole exhibits non-linear, dose-dependent pharmacokinetics due
to the saturation of its metabolic pathways.
*Explanation: Voriconazole displays saturation kinetics (Michaelis-Menten kinetics), meaning
small dose increases can lead to disproportionately high serum concentrations. This makes
therapeutic drug monitoring (TDM) essential. It is a CYP inhibitor, not an inducer, and it is
hepatically metabolized.
Question 3: Which mechanism of action is responsible for the bactericidal activity of
Daptomycin, and why is it contraindicated in the treatment of pneumonia?
A) Inhibition of cell wall synthesis; it is inactivated by binding to pulmonary surfactant.
B) Disruption of the cell membrane via depolarization; it is inactivated by pulmonary surfactant.
C) Inhibition of protein synthesis at the 50S ribosomal subunit; it is poorly distributed into the
alveolar lining fluid.
D) Interference with DNA gyrase; it lacks the necessary penetration into dense necrotic
pulmonary tissue.
Correct Answer: B) Disruption of the cell membrane via depolarization; it is inactivated by
pulmonary surfactant.
*Explanation: Daptomycin is a lipopeptide that causes calcium-dependent membrane
depolarization, leading to rapid cell death. However, it is inactivated by pulmonary surfactant,
rendering it ineffective for treating pneumonia.
Question 4: A patient is prescribed Linezolid for a Vancomycin-Resistant Enterococcus (VRE)
infection. Which of the following drug-drug interactions must be screened for to prevent the
development of Serotonin Syndrome?
A) Concurrent administration with SSRIs or SNRIs due to Linezolid’s weak reversible MAO
inhibition.
B) Concurrent administration with calcium channel blockers, which potentiate Linezolid’s
inhibitory effect on mitochondrial protein synthesis.
C) Concurrent administration with loop diuretics, which compete for renal tubular secretion.
Antimicrobial Stewardship &
Pharmacodynamics Practice Questions &
Detailed Explanations
Subject: NURS 5334 – Antimicrobial Pharmacotherapy and Advanced Clinical
Management
Question 1: A patient with a documented history of severe IgE-mediated hypersensitivity to
penicillin presents with a complex skin and soft tissue infection caused by MRSA. Which of the
following represents the most appropriate evidence-based selection, considering
pharmacodynamic safety and efficacy?
A) Cefazolin, administered with aggressive desensitization protocols.
B) Ceftriaxone, as the risk of cross-reactivity with third-generation cephalosporins is negligible.
C) Vancomycin, with targeted trough monitoring to ensure appropriate area under the curve
(AUC) targeting.
D) Imipenem-cilastatin, which exhibits a broad-spectrum profile suitable for multi-drug resistant
pathogens.
Correct Answer: C) Vancomycin, with targeted trough monitoring to ensure appropriate
area under the curve (AUC) targeting.
*Explanation: In a patient with a severe type I penicillin allergy, avoiding all beta-lactams is the
safest clinical approach when alternatives exist. Vancomycin remains the gold standard for
MRSA. AUC/MIC targeting is the current standard of practice to maximize efficacy and
minimize nephrotoxicity, unlike trough-only monitoring which is now considered outdated.
Question 2: An immunocompromised patient is diagnosed with invasive pulmonary
aspergillosis. Which pharmacodynamic property is critical to consider when initiating therapy
with Voriconazole?
A) Voriconazole acts as a potent inducer of the CYP3A4 enzyme system, requiring dosage
reductions of concomitant immunosuppressants.
B) Voriconazole exhibits non-linear, dose-dependent pharmacokinetics due to the saturation of
its metabolic pathways.
, C) Voriconazole is primarily excreted via renal filtration, necessitating significant dose
adjustments in patients with chronic kidney disease.
D) Voriconazole binds irreversibly to fungal ergosterol, leading to immediate cell membrane
lysis.
Correct Answer: B) Voriconazole exhibits non-linear, dose-dependent pharmacokinetics due
to the saturation of its metabolic pathways.
*Explanation: Voriconazole displays saturation kinetics (Michaelis-Menten kinetics), meaning
small dose increases can lead to disproportionately high serum concentrations. This makes
therapeutic drug monitoring (TDM) essential. It is a CYP inhibitor, not an inducer, and it is
hepatically metabolized.
Question 3: Which mechanism of action is responsible for the bactericidal activity of
Daptomycin, and why is it contraindicated in the treatment of pneumonia?
A) Inhibition of cell wall synthesis; it is inactivated by binding to pulmonary surfactant.
B) Disruption of the cell membrane via depolarization; it is inactivated by pulmonary surfactant.
C) Inhibition of protein synthesis at the 50S ribosomal subunit; it is poorly distributed into the
alveolar lining fluid.
D) Interference with DNA gyrase; it lacks the necessary penetration into dense necrotic
pulmonary tissue.
Correct Answer: B) Disruption of the cell membrane via depolarization; it is inactivated by
pulmonary surfactant.
*Explanation: Daptomycin is a lipopeptide that causes calcium-dependent membrane
depolarization, leading to rapid cell death. However, it is inactivated by pulmonary surfactant,
rendering it ineffective for treating pneumonia.
Question 4: A patient is prescribed Linezolid for a Vancomycin-Resistant Enterococcus (VRE)
infection. Which of the following drug-drug interactions must be screened for to prevent the
development of Serotonin Syndrome?
A) Concurrent administration with SSRIs or SNRIs due to Linezolid’s weak reversible MAO
inhibition.
B) Concurrent administration with calcium channel blockers, which potentiate Linezolid’s
inhibitory effect on mitochondrial protein synthesis.
C) Concurrent administration with loop diuretics, which compete for renal tubular secretion.
